If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Medical Affairs » Medical Affairs Excellence
Download FREE Excerpt
12 Info Graphics
17 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
As the importance of the Medical Affairs function continues to grow, top biopharma companies have developed high-impact training and development programs to help Medical Affairs professionals succeed in their critical, multifaceted roles.
Best Practices, LLC undertook this benchmarking research to examine best-in-class practices that leading biopharma organizations have implemented to create effective training oversight and curriculums.
This study will help companies maximize the benefits of their training and development programs, producing Medical Affairs staff capable of strong strategic thinking, critical communication with internal and external stakeholders, effective thought leader management, and high-impact field interactions.
Training and development leaders in medical affairs can use this study to compare their programs with those at best-in-class companies.
This study includes three data segments: Total Benchmark Class, 57; More Mature Segment, 29; and Less Mature Segment, 28
I. Training Oversight & Approvals
Best Practices, LLC engaged 57 Medical Affairs and training leaders at 42 companies. These leaders are involved with Medical Affairs training at their organizations. In-depth interviews were conducted with 5 participants to highlight often-used training practices.
Pharmaceutical; Biotech; Laboratories; Biopharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care; Chemical; Consulting; Communications; Clinical Research; Education
Adamas Pharmaceuticals; Alcon Laboratories; Alkem; Arena Pharmaceuticals; Astellas; AstraZeneca; AveXis; Bayer; Biogen; Dendreon Pharmaceuticals LLC; Eisai; EMD Serono; Endo Pharmaceuticals; Ferring Pharmaceuticals; Fidia; Gedeon Richter ; Genentech; Heron Therapeutics; Indegene; Ipsen; IQVIA; Karyopharm Therapeutics; Mallinckrodt; MEDiSTRAVA; Merck; NexGen Healthcare Communications; Novartis; Novo Nordisk; Pfizer; PTC Therapeutics; Inc.; Sanofi; Retrophin; Rhythm Pharmaceuticals; Sanofi Genzyme; Sunovion; Terumo Corporation; Teva Pharmaceutical Industries Ltd; TG Therapeutics; UCB Pharma; United Therapeutics; Versant
If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.